DOCSLIB.ORG

Author Index

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Author Index Author Index Adams, Erin J., 7001 Chang, Judy, 6629 Fairfax, Kirsten, 6563 Al-Alwan, Monther, 6961 Chang, Sun-Young, 6799 Fallon, Padraic G., 7057 Alonzo, Eric S., 6746 Charrie`re, Guillaume, 7030 Fan, Yijun, 7288 Amor, Sandra, 6929 Charriere, Guillaume M., 7071 Farmer, Jocelyn R., 7010 Andreasson, Katrin, 7207 Chau, Nguyen Van Vinh, 7281 Farrar, Jeremy, 7281 Andrew, Peter W, 7108 Cheng, Wan-Chien, 6815 Faubion, William A., Jr., 7247 Angelini, Daniela F., 6658 Chien, Jien-Wen, 7229 Fazilleau, Nicolas, 6569 August, Avery, 6807 Chittenden, Meredith, 6756 Ferguson, Thomas A., 6766 Axthelm, Michael T., 6739 Christy, Alison L., 6891 Fernandes, Vitor E., 7108 Chu, Ching-Liang, 6815 Feske, Stefan, 7305 Cˇ icˇin-Sˇain, Luka, 6739 Filippi, Christophe M., 7100 Baghat, Aabed, 6929 Clement, Marc, 6585 Filippini, Antonio, 6658 Bagley, Steve, 6938 Cobb, Robin Milley, 6970 Finke-Dwyer, Jennifer, 7082 Bain, Calum C., 6843 Coffer, Paul J., 6600 Fire, Andrew Z., 6986 Bajramovic, Jeffrey J., 6929 Coisne, Caroline, 7196 Firestein, Gary S., 7162 Bakker, Arjen Q., 6670 Collet, Xavier, 6920 Fischer, Miranda, 6739 Barbu, Emilia Alina, 7178 Collins, Andrew M., 6986 Flajnik, Martin F., 6950 Barilleau, E´ milie, 6855 Cooper, Kiesha, 7186 Foerster, Christian, 7305 Bartulis, Sarah J., 7001 Corcoran, Lynn M., 6592 Fornasa, Giulia, 6585 Bates, Mary Ellen, 7125 Court, Nathalie, 7057 Fourcade, Julien, 6709 Battistini, Luca, 6658 Coyne, Jessica J., 7040 Foureau, David M., 7022 Becker, Amy M., 6822 Criscitiello, Michael F., 6950 Fournie´, Jean-Jacques, 6680 Bell, Michael P., 7247 Crowson, Cynthia S., 7297 Franek, Beverly S., 7001 Be´nichou, Serge, 7030 Cruse, Glenn, 7108 Fre´mond, Ce´cile, 7057 Berardinelli, Andrew J., 7186 Cui, Huijuan, 6773 Frey, Benjamin, 7238 Bertics, Paul J., 7125 Currier, Noreen, 6739 Fruchon, Se´verine, 6680 Biessen, Erik, 7030 Fu, Earl, 6815 Bilenki, Laura, 7288 Fuller, Stephen J., 7040 Blackwell, Jenefer M., 7040 Dahlberg, Leif E., 6882 Funk, Holly M., 7219 Blaylock, Morgan, 6938 Daniely, Danielle, 6865 Blevins, Jon S., 6822 David, Jean-Pierre, 7238 Blom, Bianca, 6670 Davis, Daniel M., 6901 Gabriel, Sherine E., 7297 Bokarewa, Maria, 6882 Davis, John M., III, 7297 Galli, Roberta, 6658 Bonneville, Marc, 6731 De Cesaris, Paola, 6658 Gao, Bin, 6910 Boone, David L., 7001 De La Salle, Henri, 6731 Gao, Xiaoling, 7288 Bordon, Yvonne, 6843 de Salort, Jose, 7108 Gae¨ta, Bruno A., 6986 Bouchet, Je´roˆme, 7030 Debeaupuis, Emilie, 6731 Gaston, Anh-Thu, 6585 Boulter, Nicola R., 7040 Deevi, Ravi K., 6575 Gaudray, Florence, 6790 Boyd, Scott D., 6986 Dejardin, Stephanie, 7071 Gebhart, Catherine L., 7082 Boyer, Laurent, 7071 Demetris, Anthony J., 6649 Gendelman, Howard E., 7082 Bracke, Ken R., 7169 Deng, Guo-Min, 7154 Gerritsen, Wouter H., 6929 Bradding, Peter, 7108 Dewhurst, Stephen, 7082 Giles, Ian P., 6622 Bradley, Daniel G., 6993 Dib, Karim, 6575 Gilham, David E., 6938 Branch, Ware, 6622 Dillon, Stephanie M., 6612 Goldacker, Sigune, 7305 Braun, Michel Y., 6790 Doane, Cynthia J., 6739 Golden, Sarah, 7144 Brazil, Jennifer C., 7186 Dominguez, Ana Lucia, 6833 Gorantla, Santhi, 7082 Bresson, Damien, 7100 Domm, William, 7082 Gordon, Siamon, 7057 Brewin, Hannah, 7108 Dong, Tao, 7281 Gounni, Abdelilah S., 7134 Bridgeman, John S., 6938 Dontje, Wendy, 6670 Griffith, Thomas S., 6766 Brink, Robert, 6592 Downing, Tim, 6993 Guiraldelli, Michel F., 7178 Brisslert, Mikael, 6882 Drew, Angela F., 7219 Gutenberger, Sylvia, 7305 Brown, Melissa A., 6891 Driks, Adam, 6782 Brusselle, Guy G., 7169 Drummen, Nadja E. A., 7169 Bsibsi, Malika, 6929 Duncan, Lidia M., 6978 Halayko, Andrew J., 7134 Buhrman, Jonathan, 6612 Dung, Nguyen Thi Phuong, 7281 Han, Xiaobing, 7288 Buitenhuis, Miranda, 6600 Dussiot, Michael, 6585 Hanauer, Stephen B., 7001 Burgevin, Anne, 6855 Duyen, Huynh Thi Le, 7281 Hanczaruk, Bozena, 6986 Busa`, Roberta, 6658 Hargrave, Aubrey C., 7040 Buzoni-Gatel, Dominique, 7022 Earp, H. Shelton, 6637 Hawkins, Robert E., 6938 Byrd, Laura, 6739 Echasserieau, Klara, 6731 Hazen, Stanley L., 6882 Egan, Larry J., 7247 Hazzan, Marc, 6790 Caligiuri, Giuseppina, 6585 Egholm, Michael, 6986 Hehlgans, Thomas, 6688 Callis, Gayle, 7144 Ehrhardt, Katrin, 7100 Hellvard, Annelie, 6882 Cantor, Harvey, 6585 Eidson, Maggie, 6746 Herbelin, Andre´, 6585 Capietto, Aude-He´le`ne, 6680 Eissmann, Philipp, 6901 Hess, Andreas, 7238 Cappillino, Michael P., 7071 Eitson, Jennifer L., 6822 Heuser, Rose G., 7125 Carroll, Christopher J., 6622 El-Hafnawy, Talal, 6709 Hien, Tran Tinh, 7281 Cebula, Anna, 6865 Ellis, Nathan A., 7001 Hirata, Koichi, 7092 Cendron, Delphine, 6680 Engelhardt, Britta, 7196 Hobbs, Theodore, 6739 Cha, Hye-Ran, 6799 Engelke, Klaus, 7238 Hodgkin, Philip D., 6592 Chakir, Jamila, 7134 Enzmann, Gaby, 7196 Hoelzinger, Dominique B., 6833 Champagne, Eric, 6920 Estes, Elizabeth A., 7100 Holderness, Kathryn, 7144 Chang, Jae-Hoon, 6799 Evans, J. Henry, 6901 Holland, Mark, 6938 Copyright Ó 2010 by The American Association of Immunologists, Inc. 0022-1767/10/$16.00 7318 AUTHOR INDEX Holterman, Mark J., 6695 Legoux, Franc¸ois, 6731 Nedvetzki, Shlomo, 6901 Hostetler, Lydia A., 6612 Lehner, Paul J., 6978 Ness-Schwickerath, Kristin J., 7268 Hotchkiss, Richard S., 6766 Lewinsohn, Deborah A., 6739 Ngoc, Tran Van, 7281 Hou, Sen, 6961 Li, Jia, 6773 Nguyen, Khoa D., 6986 Howe, Rawleigh, 6612 Li, Qi, 6649 Nichols, Kim E., 6746 Hu, Jiping, 7047 Li, Ruobing, 6695 Nicoletti, Antonino, 6585 Huang, Ling, 6874 Lin, Ching-Yuang, 7229 Niedergang, Florence, 7030 Huang, Peng, 6910 Lin, Patricia W., 7186 Niewold, Timothy B., 7001 Huang, Ren-Yeong, 6815 Liu, Changzhen, 6910 Nikolich-Zˇ ugich, Dragana, 6739 Huang, Shengfeng, 6874 Liu, Huiling, 6874 Nikolich-Zˇ ugich, Janko, 6739 Huitinga, Inge, 6929 Liu, Lena, 7154 Nimmerjahn, Falk, 7238 Hu¨nig, Thomas, 7238 Liu, Lin Ying, 7125 Niu, Dau-Ming, 7229 Lloyd, Andrew T., 6993 Norgard, Michael V., 6822 Lodolce, James P., 7001 Noval Rivas, Magali, 6790 Ignatowicz, Leszek, 6865 Logsdon, Mark F., 7001 Ip, W. K. Eddie, 7071 Louis, Nancy A., 7186 Isenberg, David A., 6622 O’Farrelly, Cliona, 6993 Luo, Xiaobing, 6773 Oberbarnscheidt, Martin H., 6649 Luo, Xunrong, 6629 Ohta, Yuko, 6950 Jackson, Katherine J., 6986 Lustgarten, Joseph, 6833 Okuya, Koichi, 7092 Jain, Pooja, 7196 Luther, Julia, 7238 Oldham, Janine E., 7100 Jamieson, Sarra E., 7040 Oltz, Eugene M., 6970 Janjic, Bratislav, 6709 Maillet, Isabelle, 7057 Onoe, Takashi, 6756 Janssen, Harry L.A., 6600 Makarov, Edward, 7082 Oppenheim, Joost J., 6688 Jarjour, Nizar N., 7125 Makondo, Kennedy, 6961 Osipovich, Oleg, 6970 Jin, Chenggang, 7268 Mallozzi, Michael, 6782 OuYang, Chun-Nan, 6815 Jin, Yan, 6807 Maniar, Jay M., 6986 Owens, Raymond J., 6910 Johansson, Jenny, 7207 Manrique, Soraya Zorro, 6833 Johnston, James A., 6575 Maridonneau-Parini, Isabelle, 7030 Paluch, Andrew M., 7219 Jolly, Meenakshi, 7001 Marinas, Marta S., 7108 Pan, Wen, 6773 Jones, Carol D., 6986 Marshall, Aaron J., 6961 Pankhania, Depesh, 7108 Joos, Guy F., 7169 Marshall, Eleanor L., 6986 Paone, Alessio, 6658 Martinet, Ludovic, 6680 Park, Byung, 6739 Kadam, Archana P., 7116 Martinez, Laurent O., 6920 Parkos, Charles A., 7186 Kadioglu, Aras, 7108 Matsushima, Glenn K., 6637 Pascual, David W., 7144 Kalscheuer, Hannes, 6756 Matteson, Eric L., 7297 Paul, William, 6569 Kariuki, Silvia N., 7001 Mauvais, Franc¸ois-Xavier, 6855 Pauwels, Nele S. A., 7169 Karumuthil-Melethil, Subha, 6695 Mayer, Gerlinde, 7257 Peltier, Daniel C., 7010 Kasper, Lloyd H., 7022 Mazzolini, Julie, 7030 Perera, Minoli A., 7001 Kaveri, Srinivas, 6585 McCarter, Martin D., 6612 Perez, Nicolas, 6695 Kazama, Hirotaka, 6766 McDonough, Jacqueline S., 6766 Pericleous, Charis, 6622 Keller, Baerbel, 7305 McFarland-Mancini, Molly M., 7219 Pe´rigaud, Christian, 6920 Kelly, Brent C., 7047 McGreal, Nancy M., 7001 Perret, Bertrand, 6920 Kern, Joanna, 6865 McHeyzer-Williams, Michael, 6569 Persoon-Deen, Carla, 6929 Khallou-Laschet, Jamila, 6585 McKinney, E. Churchill, 6950 Peter, Hans-Hartmut, 7305 Kim, Chang-Hoon, 6799 McLeod, Rima, 7040 Peyrottes, Suzanne, 6920 Kim, Hye-Jung, 6585 Medeiros, Jennifer J., 6822 Pierangeli, Silvia S., 6622 Kim, Jae-Ouk, 6799 Medina, Indira, 7030 Platt, Andrew M., 6843 Kimbler, Trevor B., 7162 Mehrabi, Maryam, 6901 Podojil, Joseph R., 6629 Kirkwood, John M., 6709 Menard, Laurence C., 7022 Poluektova, Larisa Y., 7082 Kissenpfennig, Adrien, 6575 Mendoza, Mary, 7178 Pont, Fre´de´ric, 6680 Kita, Hirohito, 7125 Mercer, Carol A., 7219 Prabhakar, Bellur S., 6695 Knight, Katherine L., 6782 Merker, Jason D., 6986 Knutson, Keith L., 7297 Michaelis, Kai, 7257 Qi, Qian, 6807 Kochetkova, Irina, 7144 Midtling, Emilie H., 7247 Qiu, Hongyu, 7288 Kollias, George, 7238 Mielcarz, Daniel W., 7022 Quesniaux, Vale´rie F. J., 7057 Kolodziej, Lauren E., 7001 Miklos, David B., 6986 Kondilis-Mangum, Hrisavgi D., 6970 Miller, Catherine M., 7040 Rahman, Anisur, 6622 Koney-Dash, Madhuri, 6575 Miller, David J., 7010 Rahman, Meher K., 7247 Koudelka, Caroline, 6739 Miller, Stephen D., 6629 Raimer, Sharon S., 7047 Kovalovsky, Damian, 6746 Milner, Joshua D., 6569 Rakhmanov, Mirzokhid, 7305 Kozma, Sara C., 7219 Mirpuri, Julie, 7186 Ravkov, Eugene V., 6719 Krangel, Michael S., 6970 Mirza, Noweeda, 6833 Redhu, Naresh Singh, 7134 Kratzer, Roland, 6855 Mitchell, Diana M., 6719 Ren, Jingshan, 6910 Kros, Alexander, 6929 Montine, Thomas J., 7207 Rhee, Lesley, 7001 Kudela, Pavol, 6709 Mookerjee-Basu, Jayati, 6920 Riccioli, Anna, 6658 Kutomi, Goro, 7092 Moore, Kathryn J., 7071 Rice, Jurhee, 6622 Kweon, Mi-Na, 6799 Mori, Motomi, 6739 Rinner, Beate, 7257 Kyttaris, Vasileios C., 7154 Morita, Craig T., 7268 Robinson, Tammie,
Load more

Recommended publications
  • Pitolisant (Wakix) Reference Number: CP.PMN.221 Effective Date: 03.01.20 Last Review Date: 02.21 Line of Business: Commercial, HIM, Medicaid Revision Log
    Clinical Policy: Pitolisant (Wakix) Reference Number: CP.PMN.221 Effective Date: 03.01.20 Last Review Date: 02.21 Line of Business: Commercial, HIM, Medicaid Revision Log See Important Reminder at the end of this policy for important regulatory and legal information. Description ® Wakix (pitolisant) is a selective histamine 3 (H3) receptor antagonist/inverse agonist. FDA Approved Indication(s) Wakix is indicated for the treatment of excessive daytime sleepiness (EDS) or cataplexy in adult patients with narcolepsy. Policy/Criteria Provider must submit documentation (such as office chart notes, lab results or other clinical information) supporting that member has met all approval criteria. It is the policy of health plans affiliated with Centene Corporation® that Wakix is medically necessary when the following criteria are met: I. Initial Approval Criteria A. Narcolepsy with Cataplexy (must meet all): 1. Diagnosis of narcolepsy with cataplexy; 2. Prescribed by or in consultation with a neurologist or sleep medicine specialist; 3. Age ≥ 18 years; 4. Failure of 2 of the following antidepressants, each used for ≥ 1 month, unless member’s age is ≥ 65, clinically significant adverse effects are experienced, or all are contraindicated: venlafaxine, fluoxetine, atomoxetine, clomipramine, protriptyline; 5. Dose does not exceed 35.6 mg (two 17.8 mg tablets) per day. Approval duration: Medicaid/HIM – 12 months Commercial – Length of Benefit B. Narcolepsy with Excessive Daytime Sleepiness (must meet all): 1. Diagnosis of narcolepsy with EDS; 2. Prescribed by or in consultation with a neurologist or sleep medicine specialist; 3. Age ≥ 18 years; 4. Failure of a 1-month trial of one of the following central nervous system (CNS) stimulants at up to maximally indicated doses, unless clinically significant adverse effects are experienced or all are contraindicated: amphetamine immediate-release (IR), amphetamine, dextroamphetamine IR, dextroamphetamine, methylphenidate IR; *Prior authorization may be required for CNS stimulants Page 1 of 6 CLINICAL POLICY Pitolisant 5.
    [Show full text]
  • Histamine Receptors
    Tocris Scientific Review Series Tocri-lu-2945 Histamine Receptors Iwan de Esch and Rob Leurs Introduction Leiden/Amsterdam Center for Drug Research (LACDR), Division Histamine is one of the aminergic neurotransmitters and plays of Medicinal Chemistry, Faculty of Sciences, Vrije Universiteit an important role in the regulation of several (patho)physiological Amsterdam, De Boelelaan 1083, 1081 HV, Amsterdam, The processes. In the mammalian brain histamine is synthesised in Netherlands restricted populations of neurons that are located in the tuberomammillary nucleus of the posterior hypothalamus.1 Dr. Iwan de Esch is an assistant professor and Prof. Rob Leurs is These neurons project diffusely to most cerebral areas and have full professor and head of the Division of Medicinal Chemistry of been implicated in several brain functions (e.g. sleep/ the Leiden/Amsterdam Center of Drug Research (LACDR), VU wakefulness, hormonal secretion, cardiovascular control, University Amsterdam, The Netherlands. Since the seventies, thermoregulation, food intake, and memory formation).2 In histamine receptor research has been one of the traditional peripheral tissues, histamine is stored in mast cells, eosinophils, themes of the division. Molecular understanding of ligand- basophils, enterochromaffin cells and probably also in some receptor interaction is obtained by combining pharmacology specific neurons. Mast cell histamine plays an important role in (signal transduction, proliferation), molecular biology, receptor the pathogenesis of various allergic conditions. After mast cell modelling and the synthesis and identification of new ligands. degranulation, release of histamine leads to various well-known symptoms of allergic conditions in the skin and the airway system. In 1937, Bovet and Staub discovered compounds that antagonise the effect of histamine on these allergic reactions.3 Ever since, there has been intense research devoted towards finding novel ligands with (anti-) histaminergic activity.
    [Show full text]
  • Profile of Pitolisant in the Management of Narcolepsy: Design, Development, and Place in Therapy
    Journal name: Drug Design, Development and Therapy Article Designation: Review Year: 2018 Volume: 12 Drug Design, Development and Therapy Dovepress Running head verso: Romigi et al Running head recto: Pitolisant and narcolepsy open access to scientific and medical research DOI: 101145 Open Access Full Text Article REVIEW Profile of pitolisant in the management of narcolepsy: design, development, and place in therapy Andrea Romigi1 Abstract: Narcolepsy is a rare sleep disorder characterized by excessive daytime sleepiness and Giuseppe Vitrani1 rapid eye movement sleep dysregulation, manifesting as cataplexy and sleep paralysis, as well Temistocle Lo Giudice1 as hypnagogic and hypnopompic hallucinations. Disease onset may occur at any age, although Diego Centonze1,2 adolescents and young adults are mainly affected. Currently, the diagnosis delay ranges from Valentina Franco3 8 to 10 years and drug therapy may only attenuate symptoms. Pitolisant is a first-in-class new drug currently authorized by the European Medicines Agency to treat narcolepsy with or without 1IRCCS Istituto Neurologico cataplexy in adults and with an expanded evaluation for the treatment of neurologic diseases such Mediterraneo Neuromed, Pozzilli (IS), Italy; 2Department of System as Parkinson’s disease and epilepsy. This article reviews the pharmacokinetic and pharmacody- Medicine, University of Rome Tor namic profile of pitolisant, highlighting its effectiveness and safety in patients with narcolepsy. Vergata Rome, Italy; 3IRCCS Mondino Foundation, Pavia, Italy We performed a systematic review of the literature using PubMed, Embase, and Google Scholar. We report on the efficacy and safety data of pitolisant in narcoleptic patients regarding cataplexy episodes and subjective and objective daytime sleepiness. The development program of pitolisant was characterized by eight Phase II/III studies.
    [Show full text]
  • International Union of Basic and Clinical Pharmacology. XCVIII. Histamine Receptors
    1521-0081/67/3/601–655$25.00 http://dx.doi.org/10.1124/pr.114.010249 PHARMACOLOGICAL REVIEWS Pharmacol Rev 67:601–655, July 2015 Copyright © 2015 by The American Society for Pharmacology and Experimental Therapeutics ASSOCIATE EDITOR: ELIOT H. OHLSTEIN International Union of Basic and Clinical Pharmacology. XCVIII. Histamine Receptors Pertti Panula, Paul L. Chazot, Marlon Cowart, Ralf Gutzmer, Rob Leurs, Wai L. S. Liu, Holger Stark, Robin L. Thurmond, and Helmut L. Haas Department of Anatomy, and Neuroscience Center, University of Helsinki, Finland (P.P.); School of Biological and Biomedical Sciences, University of Durham, United Kingdom (P.L.C.); AbbVie, Inc. North Chicago, Illinois (M.C.); Department of Dermatology and Allergy, Hannover Medical School, Hannover, Germany (R.G.); Department of Medicinal Chemistry, Amsterdam Institute of Molecules, Medicines and Systems, VU University Amsterdam, The Netherlands (R.L.); Ziarco Pharma Limited, Canterbury, United Kingdom (W.L.S.L.); Institute of Pharmaceutical and Medical Chemistry (H.S.) and Institute of Neurophysiology, Medical Faculty (H.L.H.), Heinrich-Heine-University Duesseldorf, Germany; and Janssen Research & Development, LLC, San Diego, California (R.L.T.) Abstract ....................................................................................602 Downloaded from I. Introduction and Historical Perspective .....................................................602 II. Histamine H1 Receptor . ..................................................................604 A. Receptor Structure
    [Show full text]
  • Pitolisant and Other Histamine-3 Receptor Antagonists—An Update on Therapeutic Potentials and Clinical Prospects
    medicines Review Pitolisant and Other Histamine-3 Receptor Antagonists—An Update on Therapeutic Potentials and Clinical Prospects Victoria Harwell and Pius S. Fasinu * Department of Pharmaceutical Sciences, College of Pharmacy and Health Sciences, Campbell University, Buies Creek, NC 27501, USA; [email protected] * Correspondence: [email protected] Received: 28 July 2020; Accepted: 27 August 2020; Published: 1 September 2020 Abstract: Background: Besides its well-known role as a peripheral chemical mediator of immune, vascular, and cellular responses, histamine plays major roles in the central nervous system, particularly in the mediation of arousal and cognition-enhancement. These central effects are mediated by the histamine-3 auto receptors, the modulation of which is thought to be beneficial for the treatment of disorders that impair cognition or manifest with excessive daytime sleepiness. Methods: A database search of PubMed, Google Scholar, and clinicaltrials.gov was performed in June 2020. Full-text articles were screened and reviewed to provide an update on pitolisant and other histamine-3 receptor antagonists. Results: A new class of drugs—histamine-3 receptor antagonists—has emerged with the approval of pitolisant for the treatment of narcolepsy with or without cataplexy. At the recommended dose, pitolisant is well tolerated and effective. It has also been evaluated for potential therapeutic benefit in Parkinson disease, epilepsy, attention deficit hyperactivity disorder, Alzheimer’s disease, and dementia. Limited
    [Show full text]
  • Wakix (Pitolisant) C17997-A
    Prior Authorization Criteria Wakix (pitolisant) Policy Number: C17997-A CRITERIA EFFECTIVE DATES: ORIGINAL EFFECTIVE DATE LAST REVIEWED DATE NEXT REVIEW DUE BY OR BEFORE 02/01/2020 1/21/2021 4/2022 J CODE TYPE OF CRITERIA LAST P&T APPROVAL/VERSION NA RxPA Q2 2021 20210428C17997-A PRODUCTS AFFECTED: Wakix (pitolisant) DRUG CLASS: Histamine H3-Receptor Antagonist/Inverse Agonists ROUTE OF ADMINISTRATION: Oral PLACE OF SERVICE: Specialty Pharmacy The recommendation is that medications in this policy will be for pharmacy benefit coverage and patient self-administered AVAILABLE DOSAGE FORMS: Wakix TABS 4.45MG, Wakix TABS 17.8MG (bottles of 30) FDA-APPROVED USES: indicated for the treatment of excessive daytime sleepiness (EDS) or cataplexy in adult patients with narcolepsy COMPENDIAL APPROVED OFF-LABELED USES: None COVERAGE CRITERIA: INITIAL AUTHORIZATION DIAGNOSIS: excessive daytime sleepiness (EDS) with narcolepsy REQUIRED MEDICAL INFORMATION: A. EXCESSIVE DAYTIME SLEEPINESS WITH NARCOLEPSY: 1. Prescriber attests that member meets the International Classification of Sleep Disorders Third Edition and the Diagnostic and Statistical Manual of Mental Disorders Fifth Edition (ICSD-3 and DSM-5) guidelines for diagnosis of: (a) Narcolepsy Type 2 (narcolepsy without cataplexy) [i. An overnight polysomnogram followed the next day by an MSLT that demonstrates a mean sleep latency ≤ 8 minutes and at least two SOREMPs. OR (b) prescriber attests based on clinical judgement the member has symptoms suggestive of REM sleep dysfunction (e.g. frequent sleep paralysis or hypnagogic hallucinations) Molina Healthcare, Inc. confidential and proprietary © 2021 This document contains confidential and proprietary information of Molina Healthcare and cannot be reproduced, distributed, or printed without written permission from Molina Healthcare.
    [Show full text]
  • Histamine H3 Receptor Antagonists Potentiate Methamphetamine Self-Administration and Methamphetamine-Induced Accumbal Dopamine Release
    Neuropsychopharmacology (2004) 29, 705–717 & 2004 Nature Publishing Group All rights reserved 0893-133X/04 $25.00 www.neuropsychopharmacology.org Histamine H3 Receptor Antagonists Potentiate Methamphetamine Self-Administration and Methamphetamine-Induced Accumbal Dopamine Release 1,3,4 2,4 1,4 ,1 Patrik Munzar , Gianluigi Tanda , Zuzana Justinova and Steven R Goldberg* 1Preclinical Pharmacology Section, Behavioral Neuroscience Research Branch, Intramural Research Program, NIDA, NIH, Department of Health 2 and Human Services, Baltimore, MD, USA; Psychobiology Section, Medications Discovery Research Branch, Intramural Research Program, NIDA, NIH, Department of Health and Human Services, Baltimore, MD, USA Methamphetamine administration increases brain levels of histamine and neuronal histamine attenuates several of methamphetamine’s behavioral effects. The role of different subtypes of histamine receptors in this negative feedback, however, remains unclear. There is some evidence on possible involvement of histamine H3 receptors in these actions of methamphetamine. The aim of the present study was to evaluate the effects of two histamine H3 receptor antagonists, clobenpropit and thioperamide, on rewarding and neurochemical effects of methamphetamine utilizing three in vivo methodologies, drug self-administration, drug discrimination, and microdialysis in Sprague–Dawley rats. In rats self-administering methamphetamine intravenously under a fixed-ratio schedule, presession treatment with thioperamide (1.0–3.0 mg/kg, subcutaneous, s.c.) or clobenpropit (1.0–3.0 mg/kg, s.c.) potentiated the reinforcing effects of methamphetamine, as indicated by a dose-dependent increase in responding for a low 0.03 mg/kg dose of methamphetamine, that by itself failed to maintain responding above saline substitution levels, and a decrease in responding for a higher 0.06 mg/kg training dose of methamphetamine.
    [Show full text]
  • Histamine Receptor
    Histamine Receptor Histamine Receptors are a class of G protein-coupled receptors with histamine as their endogenous ligand. There are four known histamine receptors: H1 receptor, H2 receptor, H3 receptor, H4 receptor. The H1 receptor is a histamine receptor belonging to the family of Rhodopsin-like G-protein-coupled receptors. This receptor, which is activated by the biogenic amine histamine, is expressed throughout the body, to be specific, in smooth muscles, on vascular endothelial cells, in the heart, and in the central nervous system. H2 receptors are positively coupled to adenylate cyclase via Gs. It is a potent stimulant of cAMP production, which leads to activation of Protein Kinase A. Histamine H3 receptors are expressed in the central nervous system and to a lesser extent the peripheral nervous system, where they act asautoreceptors in presynaptic histaminergic neurons, and also control histamine turnover by feedback inhibition of histamine synthesis and release. The Histamine H4 receptor has been shown to be involved in mediating eosinophil shape change and mast cell chemotaxis. www.MedChemExpress.com 1 Histamine Receptor Inhibitors & Modulators (±)-Methotrimeprazine (D6) (±)-Tazifylline (dl-Methotrimeprazine D6) Cat. No.: HY-19489S Cat. No.: HY-U00018 Bioactivity: (±)-Methotrimeprazine (D6) is the deuterium labeled Bioactivity: (±)-Tazifylline is a potent, selective and long-acting Methotrimeprazine, which is a D3 dopamine and Histamine H1 histamine H1 receptor antagonist. receptor antagonist. Purity: >98% Purity: >98% Clinical Data: No Development Reported Clinical Data: No Development Reported Size: 1 mg Size: 1 mg, 5 mg, 10 mg, 20 mg ABT-239 Acrivastine Cat. No.: HY-12195 (BW825C) Cat. No.: HY-B1510 Bioactivity: ABT-239 is a novel, highly efficacious, Bioactivity: Acrivastine (BW825C) is a short acting histamine 1 non-imidazole class of H3R antagonist and a transient receptor antagonist for the treatment of allergic rhinitis.
    [Show full text]
  • Drug Monograph
    Drug Monograph Drug Name: Wakix® (pitolisant) tablets Drug Class: Narcolepsy Inhibitors Prepared For: MO HealthNet Prepared By: Conduent New Criteria Revision of Existing Criteria Executive Summary The purpose of this monograph is to provide a review of new therapy to determine whether the reviewed drug should be made available on an open Purpose: access basis to prescribers, require a clinical edit or require prior authorization for use. Dosage Forms: Wakix is available as an oral tablet containing 4.45 mg and 17.8 mg of pitolisant. Manufacturer: Manufactured for: Harmony Biosciences, LLC, Plymouth Meeting, PA 19462. The efficacy of Wakix for the treatment of excessive daytime sleepiness (EDS) in adult patients with narcolepsy was demonstrated in two randomized, placebo-controlled trials enrolling 290 patients with EDS. The primary endpoint in these trials was the change in Epworth Sleepiness Scale (ESS) from baseline and week 8. ESS is a questionnaire in which patients rate Summary of their perceived likelihood of falling asleep during usual daily activities. Findings: These trials showed a statistically significant difference in patients randomized to receive Wakix on the primary endpoint compared to placebo. Study 1: difference -3.0, 95% CI -5.6 to -0.4, p=0.0.24; Study 2: difference - 2.2, 95% CI -4.17 to -0.22. Status Clinical Edit PA Required Recommendation: Open Access PDL Type of PA Appropriate Indications Non-Preferred Criteria: No PA Required Preferred 2020 Conduent Business Services, LLC All Rights Reserved. Purpose The purpose of this monograph is to provide a review of new therapy to determine whether the reviewed drug should be considered a prior authorization drug, a clinical edit drug or an open access drug.
    [Show full text]
  • WAKIX Is Contraindicated in Patients with Severe Hepatic Impairment (4) WAKIX® Safely and Effectively
    ___________________ ____________________ HIGHLIGHTS OF PRESCRIBING INFORMATION CONTRAINDICATIONS These highlights do not include all the information needed to use WAKIX is contraindicated in patients with severe hepatic impairment (4) WAKIX® safely and effectively. See full prescribing information for _______________ _______________ WAKIX. WARNINGS AND PRECAUTIONS QT Interval Prolongation: Increases in QT interval. Avoid use with drugs that WAKIX® (pitolisant) tablets, for oral use also increase the QT interval and in patients with risk factors for prolonged Initial U.S. Approval: 2019 QT interval. Monitor patients with hepatic or renal impairment for increased QTc (5.1) __________________ _________________ INDICATIONS AND USAGE ____________________ ____________________ WAKIX is a histamine-3 (H3) receptor antagonist/inverse agonist indicated for the ADVERSE REACTIONS treatment of excessive daytime sleepiness (EDS) in adult patients with narcolepsy The most common adverse reactions (≥5% and twice placebo) for WAKIX (1) were insomnia, nausea, and anxiety (6.1) _______________ ______________ DOSAGE AND ADMINISTRATION To report SUSPECTED ADVERSE REACTIONS, contact Harmony • Administer once daily in the morning upon wakening. Biosciences at 1-800-833-7460 or FDA at 1-800-FDA-1088 or • The recommended dosage range is 17.8 mg to 35.6 mg daily. Titrate www.fda.gov/medwatch. dosage as follows: ____________________ ____________________ DRUG INTERACTIONS o Week 1: Initiate with 8.9 mg once daily • o Week 2: Increase dosage to 17.8 mg once daily Strong CYP2D6 Inhibitors: Maximum recommended dosage is 17.8 mg o Week 3: May increase to the maximum recommended dosage of once daily (2.4, 7.1) 35.6 mg once daily (2.1) • Strong CYP3A4 Inducers: Decreased exposure of WAKIX; consider • Hepatic impairment (2.2, 8.6, 12.3): dosage adjustment (2.4, 7.1) o Moderate hepatic impairment: Initial dosage is 8.9 mg once daily.
    [Show full text]
  • Ciproxifan, a Histamine H3-Receptor Antagonist/Inverse Agonist, Potentiates Neurochemical and Behavioral Effects of Haloperidol in the Rat
    The Journal of Neuroscience, August 15, 2002, 22(16):7272–7280 Ciproxifan, a Histamine H3-Receptor Antagonist/Inverse Agonist, Potentiates Neurochemical and Behavioral Effects of Haloperidol in the Rat Catherine Pillot,1 Jordi Ortiz,1 Anne He´ ron,1 Sophie Ridray,1 Jean-Charles Schwartz,2 and Jean-Michel Arrang2 1Laboratoire de Physiologie, Faculte´ des Sciences Pharmaceutiques et Biologiques, 75006 Paris, France, and 2Unite´de Neurobiologie et Pharmacologie Mole´ culaire de l’Institut National de la Sante´ et de la Recherche Me´ dicale, Centre Paul Broca, 75014 Paris, France By using double in situ hybridization performed with proen- Similarly, whereas it was devoid of any motor effect when kephalin and H3-receptor riboprobes on the same sections used alone, ciproxifan strongly potentiated haloperidol-induced from rat brain, we show that histamine H3 receptors are ex- locomotor hypoactivity and catalepsy, two behaviors in which pressed within striatopallidal neurons of the indirect movement striatal neurons are involved. The strong H3-receptor mRNA pathway. The majority (ϳ70%) of striatal enkephalin neurons expression in enkephalin neurons suggests that the synergistic express H3-receptor mRNAs. neurochemical and motor effects of ciproxifan and haloperidol This important degree of coexpression of proenkephalin and result from direct H3 /D2-receptor interactions, leading to an H3-receptor mRNAs prompted us to explore the effect of H3- enhanced activation of striatopallidal neurons of the indirect receptor ligands on the regulation of enkephalin mRNA expression movement pathway. The potentiation of the effects of haloper- in the striatum. Acute administration of ciproxifan, a H -receptor 3 idol by ciproxifan strengthens the potential interest of H - antagonist/inverse agonist, did not modify the expression of the 3 receptor antagonists/inverse agonists to improve the symptom- neuropeptide by itself but strongly increased the upregulation of atic treatment of schizophrenia.
    [Show full text]
  • Multiple Targeting Approaches on Histamine H3 Receptor Antagonists
    REVIEW published: 30 May 2016 doi: 10.3389/fnins.2016.00201 Multiple Targeting Approaches on Histamine H3 Receptor Antagonists Mohammad A. Khanfar 1, 2 †, Anna Affini 1 †, Kiril Lutsenko 1 †, Katarina Nikolic 3, Stefania Butini 4 and Holger Stark 1* 1 Stark Lab, Institut fuer Pharmazeutische and Medizinische Chemie, Heinrich-Heine-Universitaet Duesseldorf, Duesseldorf, Germany, 2 Faculty of Pharmacy, The University of Jordan, Amman, Jordan, 3 Department of Pharmaceutical Chemistry, Faculty of Pharmacy, University of Belgrade, Belgrade, Serbia, 4 Department of Biotechnology, Chemistry, and Pharmacy, European Research Centre for Drug Discovery and Development, University of Siena, Siena, Italy With the very recent market approval of pitolisant (Wakix®), the interest in clinical applications of novel multifunctional histamine H3 receptor antagonists has clearly increased. Since histamine H3 receptor antagonists in clinical development have been tested for a variety of different indications, the combination of pharmacological properties in one molecule for improved pharmacological effects and reduced unwanted side-effects is rationally based on the increasing knowledge on the complex neurotransmitter regulations. The polypharmacological approaches on histamine H3 receptor antagonists on different G-protein coupled receptors, transporters, enzymes as well as on NO-signaling mechanism are described, supported with some lead structures. Edited by: Giuseppe Di Giovanni, Keywords: multiple targeting, GPCR, enzymes, NO, histamine, transporter University of Malta, Malta Reviewed by: Peter McCormick, INTRODUCTION University of Barcelona, Spain Wladyslaw Lason, The idea of synthesizing multiple targeting compounds arises from the fact that the paradigm “one Polish Academy of Sciences, Poland drug—one target” or “single-target drug” is not sufficiently meeting the need for the treatment of *Correspondence: a large number of complex diseases caused by multifunctional pathophysiological processes.
    [Show full text]